clofarabine has been researched along with Minimal Disease, Residual in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bakkus, M; Beel, K; Bellido, M; Beverloo, HB; Biemond, BJ; Boersma, RS; Breems, DA; Cornelissen, JJ; de Haas, V; de Weerdt, O; Deeren, D; Fijnheer, R; Gadisseur, A; Halkes, CJM; Havelange, V; Homburg, CHE; Jaspers, A; Legdeur, MC; Legrand, O; Maertens, JA; Mazure, D; Rijneveld, AW; Selleslag, D; Sinnige, HAM; Terpstra, WE; Tick, LW; Triffet, A; van de Loosdrecht, AA; van der Holt, B; van der Velden, VHJ; van der Velden, WJFM; van der Wagen, LE; van Gelder, M; van Lammeren-Venema, D; van Sluis, GL | 1 |
| Cloos, J; Hanekamp, D; Janssen, JJWM; Ngai, LL; Ossenkoppele, GJ; van de Loosdrecht, A | 1 |
| Borkhardt, A; Dilloo, D; Escherich, G; Faber, J; Feuchtinger, T; Horstmann, MA; Imschweiler, T; Jorch, N; Pekrun, A; Schmid, I; Schramm, F; Spohn, M; Zimmermann, M; Zur Stadt, U | 1 |
| Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E | 1 |
| Escherich, G; Horstmann, MA; Zimmermann, M; Zur Stadt, U | 1 |
| Burke, MJ; Gorman, MF; Gossai, N; Karras, NA; Patel, NJ; Verneris, MR | 1 |
| Advani, AS; Appelbaum, FR; Becker, M; Coutre, S; Elkins, S; McDonough, S; Mims, M; O'Donnell, M; Othus, M; Radich, J; Wood, B | 1 |
| Imai, K | 1 |
1 review(s) available for clofarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
5 trial(s) available for clofarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Topics: Adult; Aged; Child; Clofarabine; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm, Residual; Recurrence; Remission Induction | 2022 |
Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells.
Topics: Antimetabolites, Antineoplastic; Clofarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Treatment Outcome | 2021 |
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acut
Topics: Acute Disease; Antineoplastic Agents; Child; Clofarabine; Cytarabine; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2022 |
Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Asparaginase; Child; Child, Preschool; Clofarabine; Drug Administration Schedule; Female; Humans; Male; Neoplasm, Residual; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2013 |
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Cytarabine; Febrile Neutropenia; Female; Heart Arrest; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Young Adult | 2014 |
2 other study(ies) available for clofarabine and Minimal Disease, Residual
| Article | Year |
|---|---|
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imidazoles; Immunophenotyping; Mutation; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyridazines; Recurrence; Salvage Therapy; Transplantation, Homologous | 2017 |
A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).
Topics: Adenine Nucleotides; Adolescent; Antimetabolites, Antineoplastic; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2014 |